Published in Int J Mol Sci on May 02, 2013
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. Genome Res (2013) 1.15
PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A (2014) 0.93
Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol (2014) 0.84
High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma. BMC Cancer (2015) 0.84
Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival. Int J Clin Exp Pathol (2013) 0.82
Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells. J Hematol Oncol (2014) 0.81
The role of KIF14 in patient-derived primary cultures of high-grade serous ovarian cancer cells. J Ovarian Res (2014) 0.79
Effect of targeted ovarian cancer therapy using amniotic fluid mesenchymal stem cells transfected with enhanced green fluorescent protein-human interleukin-2 in vivo. Mol Med Rep (2015) 0.76
Inhibition of ovarian cancer proliferation and invasion by pachymic acid. Int J Clin Exp Pathol (2015) 0.75
Functional redundancy of the Notch pathway in ovarian cancer cell lines. Oncol Lett (2016) 0.75
Clinical implication of Tiam1 overexpression in the prognosis of patients with serous ovarian carcinoma. Oncol Lett (2016) 0.75
Inhibitory effects of delphinidin on the proliferation of ovarian cancer cells via PI3K/AKT and ERK 1/2 MAPK signal transduction. Oncol Lett (2017) 0.75
In vitro and in silico characterization of angiogenic inhibitors from Sophora interrupta. J Mol Model (2016) 0.75
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol (2000) 13.46
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
EGFR and cancer prognosis. Eur J Cancer (2001) 7.52
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
BRCA1 mutations in primary breast and ovarian carcinomas. Science (1994) 6.81
Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res (2003) 6.43
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res (2007) 5.25
In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature (2000) 4.38
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol (2010) 3.33
New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol (2008) 3.26
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet (1992) 3.13
The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell (2001) 3.08
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet (2001) 2.98
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene (1995) 2.91
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther (2006) 2.76
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene (2004) 2.67
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol (2001) 2.24
Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecol Oncol (2013) 2.11
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol (2003) 2.07
Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist (2002) 1.93
Epigenetic resensitization to platinum in ovarian cancer. Cancer Res (2012) 1.88
Inherited breast and ovarian cancer. Hum Mol Genet (1995) 1.87
Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res (2012) 1.85
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol (2004) 1.85
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology (2011) 1.83
Early detection of ovarian cancer. Dis Markers (2007) 1.77
p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med (2004) 1.74
Mammalian Ku86 mediates chromosomal fusions and apoptosis caused by critically short telomeres. EMBO J (2002) 1.74
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation. Oncogene (2000) 1.59
EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis (1996) 1.57
Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J (2005) 1.56
Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett (2006) 1.53
Pharmaceutical management of ovarian cancer : current status. Drugs (2008) 1.52
My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol (2007) 1.50
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer (1991) 1.44
mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res (2009) 1.39
Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res (2006) 1.36
Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13. Br J Cancer (1995) 1.33
Histological classification of ovarian cancer. Med Electron Microsc (2003) 1.30
Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res (2012) 1.27
Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur J Cancer (1995) 1.27
Signalling pathways initiated by receptor protein tyrosine kinases in Drosophila. Curr Opin Cell Biol (1994) 1.25
Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis (2005) 1.23
Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther (2010) 1.21
Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol (2000) 1.19
DNA polymerase stalling, sister chromatid recombination and the BRCA genes. Oncogene (2000) 1.19
Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol (2008) 1.14
Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol (2005) 1.13
The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention". Clin Obstet Gynecol (2012) 1.13
Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res (2004) 1.11
Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer (2008) 1.09
Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med (2009) 1.09
Ovarian cancer, version 3.2012. J Natl Compr Canc Netw (2012) 1.08
A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res (2002) 1.08
Mucinous ovarian cancer. Int J Gynecol Cancer (2007) 1.07
Ovarian cancer: diagnosis and treatment. Dtsch Arztebl Int (2011) 1.05
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol (2008) 1.05
Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals. Discov Med (2012) 1.04
Natural products triggering biological targets--a review of the anti-inflammatory phytochemicals targeting the arachidonic acid pathway in allergy asthma and rheumatoid arthritis. Curr Drug Targets (2011) 1.01
Current status on biologic therapies in the treatment of epithelial ovarian cancer. Curr Treat Options Oncol (2009) 0.99
BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer (2012) 0.98
Insights into the field carcinogenesis of ovarian cancer based on the nanocytology of endocervical and endometrial epithelial cells. Int J Cancer (2013) 0.97
Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol (2004) 0.96
Targeting the EGF receptor for ovarian cancer therapy. J Oncol (2009) 0.96
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.95
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol (2012) 0.95
Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway. Oncogene (2003) 0.94
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol (2011) 0.93
Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab (2002) 0.92
NSAIDs and the colon. Curr Opin Gastroenterol (2009) 0.91
Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol (2011) 0.90
Ovarian cancer: opportunity for targeted therapy. J Oncol (2011) 0.90
GRP78 Protein Expression in Ovarian Cancer Patients and Perspectives for a Drug-Targeting Approach. J Oncol (2012) 0.89
Label-free detection of ovarian cancer biomarkers using whispering gallery mode imaging. Biosens Bioelectron (2013) 0.87
Oridonin: targeting programmed cell death pathways as an anti-tumour agent. Cell Prolif (2012) 0.87
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer (2008) 0.87
Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol (1988) 0.86
Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc (2004) 0.86
Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients. Clin Biochem (2013) 0.86
Role of farletuzumab in epithelial ovarian carcinoma. Curr Pharm Des (2012) 0.84
Neuroprotective effect of wogonin: potential roles of inflammatory cytokines. Arch Pharm Res (2004) 0.83
Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther (2007) 0.83
Update on PARP1 inhibitors in ovarian cancer. Ann Oncol (2011) 0.83
Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health (2012) 0.81
Catumaxomab: in malignant ascites. Drugs (2012) 0.81
Preoperative clinical and radiological features of metastatic ovarian tumors. Arch Gynecol Obstet (2013) 0.81
[Doppler ultrasonography in the diagnosis of ovarian cysts: indications, pertinence and diagnostic criteria]. J Gynecol Obstet Biol Reprod (Paris) (2001) 0.80
TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell (2010) 3.25
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology (2010) 1.75
Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. BJU Int (2013) 1.63
Loss of hypocretin (orexin) neurons with traumatic brain injury. Ann Neurol (2009) 1.54
Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem (2012) 1.53
Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis. Hepatology (2015) 1.49
Heterogeneity in age-related white matter changes. Acta Neuropathol (2011) 1.47
Lymphotoxin β receptor signaling promotes development of autoimmune pancreatitis. Gastroenterology (2012) 1.43
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst (2013) 1.40
The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer (2014) 1.40
SUMOylation in carcinogenesis. Cancer Lett (2011) 1.29
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer (2013) 1.27
Management of the placenta in advanced abdominal pregnancies at an East african tertiary referral center. J Womens Health (Larchmt) (2010) 1.26
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients. PLoS One (2013) 1.23
Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol (2007) 1.22
High quality assessment of DNA methylation in archival tissues from colorectal cancer patients using quantitative high-resolution melting analysis. J Mol Diagn (2009) 1.21
Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. PLoS One (2013) 1.15
Lymphotoxin-dependent prion replication in inflammatory stromal cells of granulomas. Immunity (2008) 1.14
Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J Clin Oncol (2012) 1.12
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res (2008) 1.11
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer (2011) 1.09
NEMO expression in human hepatocellular carcinoma and its association with clinical outcome. Hum Pathol (2011) 1.08
Repetitive immunization enhances the susceptibility of mice to peripherally administered prions. PLoS One (2009) 1.07
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo. Mol Cancer (2010) 1.07
Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Reprod Biol (2009) 1.06
Eukaryotic translation initiation factors in cancer development and progression. Cancer Lett (2013) 1.05
Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann Neurol (2013) 1.04
The role of microRNAs in breast cancer stem cells. Int J Mol Sci (2013) 1.04
Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas. Cell Rep (2012) 1.02
Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer. Anticancer Res (2013) 1.01
Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol (2013) 1.01
A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro Oncol (2013) 1.01
C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study. Stroke (2006) 0.99
miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor. J Clin Pathol (2013) 0.99
Inverse correlation of secreted frizzled-related protein 4 and beta-catenin expression in endometrial stromal sarcomas. J Pathol (2004) 0.98
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol (2005) 0.98
The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res (2014) 0.97
High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin. J Clin Oncol (2003) 0.97
Quality control of RNA preservation and extraction from paraffin-embedded tissue: implications for RT-PCR and microarray analysis. PLoS One (2013) 0.97
Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer Res (2014) 0.96
Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an Australia New Zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. Int J Gynecol Cancer (2010) 0.96
The pluripotent renal stem cell regulator SIX2 is activated in renal neoplasms and influences cellular proliferation and migration. Hum Pathol (2012) 0.96
Treatment of Bone Metastases in Patients with Advanced Breast Cancer. Breast Care (Basel) (2012) 0.95
A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and β2 -microglobulin. Br J Haematol (2014) 0.94
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases. Breast Cancer Res Treat (2002) 0.94
Neutrophil-to-lymphocyte ratio and its association with critical limb ischemia in PAOD patients. PLoS One (2013) 0.93
Long-term follow-up after neoadjuvant chemotherapy for high-risk cervical cancer during pregnancy. Gynecol Oncol (2007) 0.92
The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer. Clin Chem Lab Med (2015) 0.91
Women's perception of sexuality during pregnancy and after birth. Aust N Z J Obstet Gynaecol (2006) 0.91
Current status of therapeutic targeting of developmental signalling pathways in oncology. Curr Pharm Biotechnol (2012) 0.91
MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res (2012) 0.91
Cross β-sheet conformation of keratin 8 is a specific feature of Mallory-Denk bodies compared with other hepatocyte inclusions. Gastroenterology (2011) 0.90
Chromosomal alterations in low-grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma as detected by comparative genomic hybridization. Gynecol Oncol (2005) 0.89
Comprehensive analysis of alterations in the miRNome in response to photodynamic treatment. J Photochem Photobiol B (2013) 0.88
Fibrin application for preventing lymphocysts after retroperitoneal lymphadenectomy in patients with gynecologic malignancies. Gynecol Oncol (2002) 0.88
AGO Austria recommendations for genetic testing of patients with ovarian cancer. Wien Klin Wochenschr (2015) 0.88
Are morphological criteria sufficient for the identification of circulating tumor cells in renal cancer? J Transl Med (2013) 0.88
The insulin-like growth factor 2 (IGF2) mRNA-binding protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC? Gut (2013) 0.88
eIF3a is over-expressed in urinary bladder cancer and influences its phenotype independent of translation initiation. Cell Oncol (Dordr) (2014) 0.88
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Clin Cancer Res (2009) 0.87
The influence of elevated levels of C-reactive protein and hypoalbuminemia on survival in patients with advanced inoperable esophageal cancer undergoing palliative treatment. J Surg Oncol (2014) 0.87
Germinal center B cells are dispensable in prion transport and neuroinvasion. J Neuroimmunol (2007) 0.87
Parametrial spread of cervical cancer in patients with negative pelvic lymph nodes. Gynecol Oncol (2002) 0.86
Clusterin expression in cholestasis, hepatocellular carcinoma and liver fibrosis. Histopathology (2009) 0.86
Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Res (2009) 0.86
Lessons learned from four advanced abdominal pregnancies at an East African Health Center. J Perinat Med (2007) 0.85
Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci (2011) 0.85
Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study. Gynecol Oncol (2005) 0.84
Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations. Histopathology (2010) 0.84
Is intraoperative frozen section analysis of pelvic lymph nodes accurate after neoadjuvant chemotherapy in patients with cervical cancer? Gynecol Oncol (2006) 0.83
Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option. Anticancer Res (2014) 0.83
O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms. J Mol Med (Berl) (2012) 0.83
Damage to histaminergic tuberomammillary neurons and other hypothalamic neurons with traumatic brain injury. Ann Neurol (2014) 0.82
High-fat diet triggers Mallory-Denk body formation through misfolding and crosslinking of excess keratin 8. Hepatology (2014) 0.82
Temperature-induced changes of magnetic resonance relaxation times in the human brain: a postmortem study. Magn Reson Med (2013) 0.82
Hedgehog signaling pathway in ovarian cancer. Int J Mol Sci (2013) 0.82
Histiocytic sarcoma - targeted therapy: novel therapeutic options? A series of 4 cases. Onkologie (2012) 0.82
The myeloperoxidase product hypochlorous acid generates irreversible high-density lipoprotein receptor inhibitors. Arterioscler Thromb Vasc Biol (2013) 0.82
Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series. J Clin Pathol (2013) 0.82
The role of polycomb repressive complexes in biliary tract cancer. Expert Opin Ther Targets (2014) 0.82
Overexpression of eIF3a in Squamous Cell Carcinoma of the Oral Cavity and Its Putative Relation to Chemotherapy Response. J Oncol (2012) 0.82
Breast metastasis 56 months before the diagnosis of primary ovarian cancer: a case study. Anticancer Res (2008) 0.82
NR4A1-mediated apoptosis suppresses lymphomagenesis and is associated with a favorable cancer-specific survival in patients with aggressive B-cell lymphomas. Blood (2014) 0.82
Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma. BMC Med Genet (2013) 0.81
A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. Mol Carcinog (2013) 0.81
The cytoskeleton in nonalcoholic steatohepatitis: 100 years old but still youthful. Expert Rev Gastroenterol Hepatol (2011) 0.81
A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients. Clin Cancer Res (2014) 0.81
Inguinal lymph node metastasis as the presenting symptom of endometrial cancer: a case report. Anticancer Res (2002) 0.81